Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Investor Presentation (May 2025)
23 slides from Prescient Therapeutics's investor presentation, May 21, 2025
Slide 1: Investor Briefing May 2025
For personal use only Investor Briefing May 2025 ASX: PTX ptxtherapeutics.com
Slide 2: Disclaimer and Safe Harbour
Disclaimer and Safe Harbour For personal use only Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts
Slide 3: Targeted RAS therapies for cancers of unmet need
For personal use only Targeted RAS therapies for cancersRAS Targeted of unmet need therapies Platforms supporting for cancers of unmet need CAR-T therapies ✔ PTX-100 ✔ PTX-100 ✔ OmniCAR ✔ CellPryme
Slide 4: PTX-100 is an advancing cancer therapy on the ASX
For personal use only ● Addressing high-mortality cancers of unmet need T Cell Lymphoma (TCL) ● Results beyond benchmarks and existing drugs ● FDA support Targeted RAS therapies ● US$1.8bn focus market* of TCL for cancers of unmet need ● In Phase 2a – with potential for 2b registration study ✔ PTX-1
Slide 5: What causes cancerous mutations?
What causes cancerous mutations? For personal use only Normal cell growth Normal cell Cell division Healthy tissue Abnormal cell growth Normal cell Genetic changes Cancerous cell division Malignant tumour Source: https://www.cancerfoundation.org.au/what-is-cancer-.html
Slide 6: PTX-100 First in Class Targeted Therapy
PTX-100 First in Class Targeted Therapy For personal use only Inhibition of GGT-1 disrupts small GTPases including: the RAS family pathway • Mutations in RAS are present in approximately 22% of all human cancers1 • PTX-100 targets and blocks an enzyme called GGTase-1, disrupting the RAS family pathw
Slide 7: Cutaneous T-cell Lymphoma (CTCL) Overview
Cutaneous T-cell Lymphoma (CTCL) Overview For personal use only ● A rare type of cancer of white blood cells (T cells), normally involved in immune function ● These cancerous T cells travel to and live in the skin, where they grow and divide uncontrollably, attacking the skin ● Limited options for p
Slide 8: Cutaneous T-cell Lymphomas (CTCL) a serious unmet need
Cutaneous T-cell Lymphomas For personal use only (CTCL) a serious unmet need “Unfortunately, T-Cell lymphomas (…) is universally incurable in patients that have not responded to initial therapy. So, we are in desperate need of a treatment that will allow patients to respond and give them
Slide 9: Patient responses before and after PTX-100
“We are seeing responses in For personal use only our patients who weren’t responding to any other BEFORE AFTER treatments” — Professor Miles Prince Principal Investigator
Slide 10: PTX-100 Phase 1b responses
PTX-100 Phase 1b responses For personal use only Strong response rates in evaluable patients PTX-100 Benchmark1 Lymphir2,3 (Phase 1B) Response Rate 30% 36% 45% Clinical Benefit Rate 45% NA 64% 9-13 months CTCL Duration of Response 6.5 months (CTCL) 10.7 months 3-4 Months PTCL Serious Adverse Events4
Slide 11: PTX-100: Favorable safety profile compared to peers
PTX-100: Favorable safety profile compared to peers For personal use only Recommended CTCL drugs, as outlined in international cancer treatment guidelines, have challenging safety profiles, with adverse events occurring in up to 70% of patients. PTX-100 HAS A FAVOURABLE SAFETY PROFILE ● Minimal ‘ser
Slide 12: The building blocks of taking PTX-100 through Phase 2
The building blocks of taking PTX-100 through Phase 2 For personal use only Study design Patient recruitment FDA engagement • CTCL vs PTCL • Geographies • Ongoing dialogue • 2a / 2b design • Clinics • Goal: registration study • Existing data • Experts • FDA inputs on Phase 2b design • Dosages • Pati
Slide 13: Rationale of prioritising r/r CTCL over PTCL for Phase 2 trial
Rationale of prioritising r/r CTCL over PTCL for Phase 2 trial For personal use only PTCL (Peripheral T Cell Lymphoma) CTCL (Cutaneous T Cell Lymphoma) More prevalent than CTCL, but… • Higher confidence – more data & responders • More existing and emerging competition • Greater need for new therapie
Slide 14: Progressing PTX-100 to Phase 2
Progressing PTX-100 to Phase 2 For personal use only 500mg/m2 x 20 pts Dose r/r CTCL Randomization confirmation 2nd Line Phase 2a Dose Phase 2b Enrolment Optimisation Optimisation Efficacy X40 patients Committee X 75 pts (pts) 1000mg/m2 x 20 pts Up to 2 years Multicenter clinical trial • Phase 2a: N
Slide 15: Aiming for shortened registrational pathway
Aiming for shortened registrational pathway For personal use only Regular drug development process Years & $$$ saved Potential for Registrational study Adapted from Capuano, A. et al; Front. In Pharmacol.; Feb 2019
Slide 16: Aiming for shortened registrational pathway
Aiming for shortened registrational pathway For personal use only PTX-100 Regular drug Benchmark1 Lymphir2,3 (Phase 1B) development process Response Rate 30% 36% 45% Clinical Benefit Rate 45% NA 64% Years & 9-13 months CTCL Duration of Response 6.5 months (CTCL) $$$ saved 10.7 months 3-4 Months PTCL
Slide 17: Advantages of orphan drugs
Advantages of orphan drugs For personal use only 7 7 years of Higher Sales are more Total orphan Consistently guaranteed prices resilient to sales to reach higher sales market cycles $US300B by growth (11.6% exclusivity 2028, in an CAGR) in US overall market than non- (10 years in of $1.5T orphan dr
Slide 18: T-cell lymphomas (TCL): High unmet need = large market opportunity
T-cell lymphomas (TCL): For personal use only High unmet need = large market opportunity Total Addressable Market (TAM) CTCL US alone • 27,263 new cases / year in the • Incidence 3,000 patients 8 major markets /annum# • Almost all will relapse • Almost all will relapse • Potential of $1.8B / year by
Slide 19: Key milestones in the near future
Key milestones in the near future Implementation will drive value For personal use only Key Milestones Expected Timing (CY) First patient in and dosed with PTX-100 (FPID) Q2 FDA Fast Track designation Q2 (Complete) EU Orphan Drug Designation Q3 First US site activated and recruiting Q3 First Europea
Slide 20: First in Class PTX-100 beyond TCL
First in Class PTX-100 beyond TCL For personal use only First in class enzyme inhibitor disrupting the RAS super - family pathway, in particular, RHO, RAC and RAL. Examples: The RAS super family of genes consists of RAL, RAC, RHO-A/B, plus N-RAS and K-RAS. There are up to 153 proteins. Some examples
Slide 21: Experienced team
Experienced team For personal use only Experienced team of drug developers and deal makers with track record in blood cancers. Management Team Experienced gained in global companies Dr Rebecca Tunstall COO Board of Directors Melanie Farris Non-Executive Director
Slide 22: Summary – PTX-100 driving a major inflection point
Summary – PTX-100 driving a major inflection point For personal use only PTX-100 in Phase 2 Wider RAS platform opportunity • Addressing an orphan disease • First in class enzyme inhibitor • Strong Phase 1 results • Multiple RAS pathways • FDA support • PTX-100 = proof of concept • Targeting registra
Slide 23: Thank you
For personal use only Thank you ASX: PTX ptxtherapeutics.com
Prescient Therapeutics — Investor Presentation (May 2025) on 6ix